Vibrent Health provides a platform designed to manage study data and processes for health and clinical research. This platform includes features for screening, electronic consent, data collection, and sharing information, all integrated into one system. By consolidating these functions, Vibrent Health makes the research process easier and more efficient for clients like research institutions and healthcare providers. The platform also offers real-time data analytics, allowing research teams to work together and gain insights quickly. Unlike many competitors, Vibrent Health focuses on enhancing participant engagement and streamlining research through precision technology and digital tools. The company's goal is to accelerate health research to improve human health.

Data & Analytics

Healthcare

Vibrent Health

As part of this collaboration, Vibrent launched a participant portal for Twin360 , built on Vibrent’s Participant Experience Manager.

How Virginia Commonwealth University Accelerated Data Collection from Twins for Long-COVID Study

The Lynch syndrome study team collaborated with Vibrent Health to provide a study infrastructure that would accelerate eConsent and data collection for participants in the cancer registry.

How Dana-Farber Cancer Institute Created a Digital Cancer Registry to Improve Cancer Research and Maximize Patient Engagement

FAIRFAX, Va.--(BUSINESS WIRE)--Multiple myeloma is a cancer of the plasma cells in bone marrow that affects more than 30,000 new patients in the United States each year. Today, multiple myeloma is still considered incurable.Nearly all people with multiple myeloma have early warning signs called "precursor conditions." Health leaders like the Dana-Farber Cancer Institute, one of the world’s leading centers of cancer research and treatment, can better treat this condition if it is detected early, and therefore reduce mortality. Now with their recent announcement about the ambitious PROMISE study, Dana-Farber aims to make multiple myeloma a cancer that is preventable.By collecting and analyzing data from people who test positive for the early precursor conditions, Dana-Farber will be able to study people before they develop the condition, in order to discover how to better treat – and ultimately prevent – this deadly cancer.A study of this magnitude requires extensive data collection, as well as an approach to enroll and engage participants from communities traditionally under-represented in biomedical and clinical research. To achieve these aims, Dana-Farber chose to collaborate with Vibrent Health, a digital technology company known for its innovation in precision medicine research solutions and providing researchers a better way to provide eConsent and collect data across electronic medical records, genomics, wearables, surveys, and more.Dana-Farber will use Vibrent’s platform for informed eConsent to enroll a highly diverse pool of research participants nationwide. Dana-Farber study staff will also use Vibrent’s platform to perform novel data collection through virtual methods and computer-assisted telephone interviewing (CATI).The Research Institute will implement patient engagement through Vibrent’s robust privacy-protecting participant portal and comprehensive researcher tools, as well as provide educational content that can be personalized to the patient’s specific and unique needs.“Using this technology to interact directly with our study participants is so powerful,” said the study’s principal investigator Irene Ghobrial, MD, of Dana-Farber. “Not only will this improve the quality of the research we are able to conduct, but it puts the tools in our participants hands to help us make multiple myeloma a preventable disease.”For Vibrent Health, this partnership builds on the company’s commitment to improving research data and health outcomes for traditionally underrepresented populations in clinical research.“Clinical research has long faced limitations because of the available participants,” said Vibrent Health CEO Praduman “PJ” Jain

Dana-Farber Cancer Institute Selects Vibrent Health’S Next-Generation Digital Health Research Platform To Enable Early Detection For The Prevention Of Multiple Myeloma

Today Vibrent Health announced the launch of a Global Twin Research Platform (GTRP), in partnership with the Virginia Commonwealth University (VCU), to better understand health similarities and differences between twins by studying the varying genetic and environmental influences on development, including physical development, intelligence, emotion and cognition.

Vibrent Health partnered with Vcu Health System on Oct 19th 21'.

University of Maryland Medicine announced a new partnership today with Vibrent Health, a health technology company based in Fairfax, Virginia, to create the All of Maryland Precision Health Initiative, a statewide digital platform for studies examining how genes and other factors affect health.

UNIVERSITY OF MARYLAND EYE ASSOCIATES PA partnered with Vibrent Health on Sep 14th 21'.

Fairfax, Virginia-based Vibrent Health then received the second grant, with both grants totaling $4 million, in June after completing phase one of its NIH project, which required organizations to demonstrate feasibility of the project.

Vibrent Health received financing of $4M in grants on Jun 1st 21'.

Vibrent Health, a health technology company powering the future of precision medicine, announced the successful launch of its Clinical Research Board (CRB), which serves as a valuable forum for the health research ecosystem to inform Vibrent Health’s technology roadmap.

Vibrent Health launches Clinical Research Board

Platform for managing clinical research data

Vibrent Health

Platform for managing clinical research data

Vibrent Health

Platform for managing clinical research data

About

Simplify's Take

What believers are saying

What critics are saying

What makes Vibrent Health unique

Recently Posted Jobs

There are no jobs for Vibrent Health right now.